283 related articles for article (PubMed ID: 17934892)
1. Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer.
Schagen SB; Boogerd W; Muller MJ; Huinink WT; Moonen L; Meinhardt W; Van Dam FS
Acta Oncol; 2008; 47(1):63-70. PubMed ID: 17934892
[TBL] [Abstract][Full Text] [Related]
2. Long-term cognitive function following chemotherapy in patients with testicular cancer.
Pedersen AD; Rossen P; Mehlsen MY; Pedersen CG; Zachariae R; von der Maase H
J Int Neuropsychol Soc; 2009 Mar; 15(2):296-301. PubMed ID: 19203434
[TBL] [Abstract][Full Text] [Related]
3. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer.
van den Belt-Dusebout AW; Nuver J; de Wit R; Gietema JA; ten Bokkel Huinink WW; Rodrigus PT; Schimmel EC; Aleman BM; van Leeuwen FE
J Clin Oncol; 2006 Jan; 24(3):467-75. PubMed ID: 16421423
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study.
Haugnes HS; Wethal T; Aass N; Dahl O; Klepp O; Langberg CW; Wilsgaard T; Bremnes RM; Fosså SD
J Clin Oncol; 2010 Oct; 28(30):4649-57. PubMed ID: 20855830
[TBL] [Abstract][Full Text] [Related]
5. A prospective study of cognitive complaints in patients with testicular cancer.
Skaali T; Fosså SD; Dahl AA
Clin Genitourin Cancer; 2011 Sep; 9(1):6-13. PubMed ID: 21729683
[TBL] [Abstract][Full Text] [Related]
6. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy.
Mehnert A; Scherwath A; Schirmer L; Schleimer B; Petersen C; Schulz-Kindermann F; Zander AR; Koch U
Patient Educ Couns; 2007 Apr; 66(1):108-18. PubMed ID: 17320337
[TBL] [Abstract][Full Text] [Related]
7. Completion and toxicity of induction chemotherapy for metastatic testicular cancer: an updated evaluation of Japanese patients.
Kawai K; Ando S; Hinotsu S; Oikawa T; Sekido N; Miyanaga N; Shimazui T; Akaza H
Jpn J Clin Oncol; 2006 Jul; 36(7):425-31. PubMed ID: 16790450
[TBL] [Abstract][Full Text] [Related]
8. [BEP-chemotherapy in patients with testicular tumors--is it worthwhile?].
Hess U; Jungi WF; Morant R; Schmid L; Senn HJ; Bandhauer K
Schweiz Med Wochenschr; 1990 Dec; 120(49):1883-6. PubMed ID: 1702233
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
[TBL] [Abstract][Full Text] [Related]
10. Management of good risk germ-cell tumours.
Troost MM; Sternberg CN; de Wit R
BJU Int; 2009 Nov; 104(9 Pt B):1387-91. PubMed ID: 19840018
[TBL] [Abstract][Full Text] [Related]
11. Variation in bleomycin hydrolase gene is associated with reduced survival after chemotherapy for testicular germ cell cancer.
de Haas EC; Zwart N; Meijer C; Nuver J; Boezen HM; Suurmeijer AJ; Hoekstra HJ; van der Steege G; Sleijfer DT; Gietema JA
J Clin Oncol; 2008 Apr; 26(11):1817-23. PubMed ID: 18398146
[TBL] [Abstract][Full Text] [Related]
12. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor.
Kang H; Kim TJ; Kim WY; Choi CH; Lee JW; Kim BG; Bae DS
Gynecol Oncol; 2008 Oct; 111(1):106-10. PubMed ID: 18656249
[TBL] [Abstract][Full Text] [Related]
13. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer.
Nuver J; Smit AJ; van der Meer J; van den Berg MP; van der Graaf WT; Meinardi MT; Sleijfer DT; Hoekstra HJ; van Gessel AI; van Roon AM; Gietema JA
J Clin Oncol; 2005 Dec; 23(36):9130-7. PubMed ID: 16301596
[TBL] [Abstract][Full Text] [Related]
14. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients.
Schagen SB; Muller MJ; Boogerd W; Mellenbergh GJ; van Dam FS
J Natl Cancer Inst; 2006 Dec; 98(23):1742-5. PubMed ID: 17148777
[TBL] [Abstract][Full Text] [Related]
15. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study.
Fan HG; Houédé-Tchen N; Yi QL; Chemerynsky I; Downie FP; Sabate K; Tannock IF
J Clin Oncol; 2005 Nov; 23(31):8025-32. PubMed ID: 16258100
[TBL] [Abstract][Full Text] [Related]
16. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer.
Tchen N; Juffs HG; Downie FP; Yi QL; Hu H; Chemerynsky I; Clemons M; Crump M; Goss PE; Warr D; Tweedale ME; Tannock IF
J Clin Oncol; 2003 Nov; 21(22):4175-83. PubMed ID: 14615445
[TBL] [Abstract][Full Text] [Related]
17. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
18. The impact of chemotherapy on cognitive function: a multicentre prospective cohort study in testicular cancer.
Whitford HS; Kalinowski P; Schembri A; Grimison P; Stockler M; Martin A; Toner GC; Davis ID; Maruff P; Olver IN;
Support Care Cancer; 2020 Jul; 28(7):3081-3091. PubMed ID: 31642990
[TBL] [Abstract][Full Text] [Related]
19. Effects of chemotherapeutic agents for testicular cancer on the male rat reproductive system, spermatozoa, and fertility.
Bieber AM; Marcon L; Hales BF; Robaire B
J Androl; 2006; 27(2):189-200. PubMed ID: 16278370
[TBL] [Abstract][Full Text] [Related]
20. One-year longitudinal study of fatigue, cognitive functions, and quality of life after adjuvant radiotherapy for breast cancer.
Noal S; Levy C; Hardouin A; Rieux C; Heutte N; Ségura C; Collet F; Allouache D; Switsers O; Delcambre C; Delozier T; Henry-Amar M; Joly F
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):795-803. PubMed ID: 20888704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
